Drug intelligence / Profile preview

T3P-1137

Development stage: Preclinical
Lead developer: Boehringer Ingelheim
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Recombinant Proteins and Enzymes, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Intravenous

Overview

T3P-1137 is an investigational microbial immunotherapy developed by T3 Pharmaceuticals (a subsidiary of Boehringer Ingelheim) for the treatment of solid tumors. It utilizes a proprietary platform based on an attenuated strain of *Salmonella typhimurium* (YS1646) engineered with a functional Type 3 Secretion System (T3SS). This system allows the bacteria to selectively colonize the hypoxic environment of solid tumors and deliver therapeutic protein payloads directly into the tumor microenvironment. T3P-1137 is specifically designed to deliver Interleukin-12 (IL-12), a potent pro-inflammatory cytokine that promotes the activation and recruitment of T cells and natural killer (NK) cells. By localizing the production and secretion of IL-12 within the tumor, T3P-1137 aims to induce a robust anti-tumor immune response while mitigating the severe systemic toxicities typically associated with recombinant IL-12 administration.

Targets

IL-12R (Interleukin-12 receptor)

Beyond the preview

Go deeper on T3P-1137.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T3P-1137.

Explore the full profile